Press releases
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Announces $180 Million Private Placement
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
More ▼
Key statistics
As of last trade, Spyre Therapeutics Inc (3920:FRA) traded at 34.20, 14.57% above the 52 week low of 29.85 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.20 |
---|---|
High | 34.20 |
Low | 34.20 |
Bid | 34.30 |
Offer | 35.45 |
Previous close | 33.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 40.28m |
Free float | 35.73m |
P/E (TTM) | -- |
Market cap | 1.52bn USD |
EPS (TTM) | -71.35 USD |
Data delayed at least 15 minutes, as of May 17 2024 07:00 BST.
More ▼